



32759 070165.0555

PATENT

reconsideration of the amended claims is requested. An early allowance is earnestly sought.

Attached hereto as **APPENDIX A** is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

Respectfully submitted,

Dated: February 11, 2002

Carmella L. Stephens

Lisa B. Kole

Patent Office Reg. No. 35,225

Carmella L. Stephens

Patent Office Reg. No. 41,328

BAKER BOTTS L.L.P.

30 Rockefeller Plaza

New York, New York 10112-0228

Attorneys for Applicants

(212) 408-2539

APPENDIX A**VERSION WITH MARKINGS TO SHOW CHANGES MADE**In the Specification:

On page 30, please delete the second full paragraph and replace it with the following paragraph:

--The anti-polycystin-1 antibody was raised in rabbits against a purified synthetic 31 amino acid peptide corresponding to amino acids 4161-4191 in the predicted intracellular portion of polycystin-1, proximal to the C-terminal: sequence LPSRSSRGSKVSPDVPPPSAGSDASHPSTSS (SEQ ID NO: 1). Antiserum specificity was confirmed by Elisa, immunoblot and immunocytochemical analyses, before and after affinity purification; by lack of staining with pre-immune sera and competition of immunoreaction by preadsorption with the appropriate peptide. Immunocytochemistry was carried out using an avidin-biotin-peroxidase system (Vectastain, Vector Laboratories) and aminoethylcarbazole as chromogen 9 (red color). Staining patterns were identical when carried out on frozen and paraformaldehyde (4%)-fixed material. 1:500 dilution of anti-polycystin-1 was used.--

IN THE CLAIMS:

Please cancel Claims 1-20, and insert the following new Claims:

--21. A method for identifying a compound capable of modulating polycystin-1 activity, comprising;

(a) contacting a test compound to a cell expressing a polycystin-1

protein wherein expression of said polycystin-1 protein results in an increase in cell adherence to type I collagen coated substrate;

(b) measuring cell adherence to type I collagen coated substrate; and

(c) comparing the level of cell adherence to type I collagen coated substrate obtained in (b) to the level of cell adherence to type I collagen coated substrate obtained in the presence of a vehicle control:

wherein if the level obtained in (b) differs from that obtained in the presence of a vehicle control, a compound capable of modulating polycystin-1 activity has been identified.

22. The method of Claim 21 wherein the cell is recombinantly engineered to express a mutant polycystin-1 protein.

23. The method of Claim 21 wherein the polycystin-1 protein is over expressed.

24. A method for identifying a compound capable of modulating polycystin-1 activity, comprising:

(a) contacting a test compound to a cell expressing a polycystin-1 protein wherein expression of said polycystin-1 protein results in an increase in apical expression of NaK-ATPase on the cell membrane;

(b) measuring an increase in apical expression of NaK-ATPase on the cell membrane; and

(c) comparing the level of an increase in apical expression of NaK-ATPase on the cell membrane obtained in (b) to the level of an increase in apical expression of NaK-ATPase on the cell membrane obtained in the presence of a vehicle

control:

wherein if the level obtained in (b) differs from that obtained in the presence of a vehicle control, a compound capable of modulating polycystin-1 activity has been identified.

25. The method of Claim 24 wherein the cell is recombinantly engineered to express a mutant polycystin-1 protein.

26. The method of Claim 24 wherein the polycystin-1 protein is over expressed.

27. A method for identifying a compound capable of modulating polycystin-1 activity, comprising;

(a) contacting a test compound to a cell expressing a polycystin-1 protein wherein expression of said polycystin-1 protein results in an increased expression of β -2-NaKATPase within the cell;

(b) measuring increased expression of β -2-NaKATPase within the cell; and

(c) comparing the level of increased expression of β -2-NaKATPase within the cell obtained in (b) to the level of increased expression of β -2-NaKATPase within the cell obtained in the presence of a vehicle control:

wherein if the level obtained in (b) differs from that obtained in the presence of a vehicle control, a compound capable of modulating polycystin-1 activity has been identified.

28. The method of Claim 27 wherein the cell is recombinantly engineered to express a mutant polycystin-1 protein.

29. The method of Claim 27, 28 or 29 wherein the polycystin-1 protein is over expressed.

30. The method of Claim 7, 8 or 9 wherein the expression of β -2-NaK-ATPase within the cell is measured using an anti- β -2-NaK-ATPase antibody.

31. A method for identifying a compound capable of modulating polycystin-1 activity, comprising;

(a) contacting a test compound to a cell expressing a polycystin-1 protein wherein expression of said polycystin-1 protein results in a decreased incorporation of focal adhesion kinase into focal adhesion complexes;

(b) measuring a decreased incorporation of focal adhesion kinase into focal adhesion complexes; and

(c) comparing the level of a decreased incorporation of focal adhesion kinase into focal adhesion complexes obtained in (b) to the level of a decreased incorporation of focal adhesion kinase into focal adhesion complexes obtained in the presence of a vehicle control:

wherein if the level obtained in (b) differs from that obtained in the presence of a vehicle control, a compound capable of modulating polycystin-1 activity has been identified.

32. The method of Claim 31 wherein the cell is recombinantly engineered to express a mutant polycystin-1 protein.

33. The method of Claim 32 wherein the polycystin-1 protein is over expressed.

34. The method of Claim 31, 32, or 33 wherein the incorporation of focal adhesion kinase into focal adhesion complexes is measured using an anti-focal adhesion kinase antibody.

35. The method of Claim 31 wherein the cell expressing the polycystin-1 protein further comprises an epitope tagged focal adhesion kinase protein.

36. The method of Claim 22, 25, 28 or 32 wherein the recombinantly engineered cell comprises an epitope tagged polycystin-1 interacting protein.

37. The method of Claim 2, 3, 5, 6, 8, 9, 12 or 13 wherein the polycystin-1 protein is epitope tagged. --